Saxenda (liraglutide 3.0 mg) is used daily as a once-daily subcutaneous injection for chronic weight management in adults and adolescents meeting specific criteria. This GLP-1 receptor agonist, licensed by the MHRA, requires consistent daily administration to maintain therapeutic drug levels and appetite-suppressing effects. Treatment follows a five-week dose escalation protocol, starting at 0.6 mg and increasing to a maintenance dose of 3.0 mg daily. Daily use must be combined with a reduced-calorie diet and increased physical activity. Understanding the dosing schedule, injection technique, and what to do if doses are missed is essential for safe and effective treatment outcomes.

Is Saxenda Used Daily? Understanding the Dosing Schedule

Yes, Saxenda is designed to be used once daily as part of a comprehensive weight management programme. Saxenda (liraglutide 3.0 mg) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as type 2 diabetes or hypertension. It is also licensed for adolescents aged 12 years and above with obesity and a body weight above 60 kg.

The daily dosing schedule is fundamental to how Saxenda works. Liraglutide has a half-life of approximately 13 hours, which means regular daily administration is necessary to maintain therapeutic drug levels in the body. The medication works by mimicking the action of GLP-1, a naturally occurring hormone that regulates appetite and food intake. By activating GLP-1 receptors in the brain, Saxenda helps reduce hunger, increase feelings of fullness, and ultimately support calorie reduction.

The treatment follows a gradual dose escalation protocol over five weeks, starting at 0.6 mg daily and increasing weekly by 0.6 mg increments until reaching the maintenance dose of 3.0 mg daily. This titration schedule is designed to improve gastrointestinal tolerability and reduce the likelihood of adverse effects such as nausea and vomiting, which are common when starting GLP-1 receptor agonists. If the 3.0 mg dose is not tolerated, a temporary down-titration or treatment discontinuation may be considered.

According to the UK product licence (SmPC), Saxenda should only be continued beyond 12 weeks on the 3.0 mg maintenance dose if patients have lost at least 5% of their initial body weight. The daily regimen must be combined with a reduced-calorie diet and increased physical activity to achieve optimal weight loss outcomes. Consistency with daily dosing is essential for maintaining the medication's appetite-suppressing effects and achieving meaningful weight reduction.

In the NHS, Saxenda may be prescribed through specialist weight management services, and local criteria may apply for access.

How to Use Saxenda: Daily Injection Guidelines

Saxenda is administered as a subcutaneous injection once daily at any time of day, with or without food. The injection must be given under the skin only—never inject into a vein or muscle. The injection can be given in the abdomen, thigh, or upper arm, and patients should rotate injection sites within the same body region to reduce the risk of local skin reactions or lumps. It is important to use a different injection spot each day, even when injecting in the same general area.

The pre-filled pen device delivers doses ranging from 0.6 mg to 3.0 mg in 0.6 mg increments. Each pen contains 18 mg of liraglutide and provides doses for several days depending on the prescribed amount. Patients should be trained by a healthcare professional on proper injection technique, including how to attach a new needle for each injection, perform a flow check before first use only, and safely dispose of used needles in a sharps container. In the UK, you should use a prescribed sharps bin and return it via your pharmacy or local council collection service when full.

For optimal consistency, many patients find it helpful to inject Saxenda at the same time each day, which can aid adherence and help establish a routine. However, the specific time is flexible and can be adjusted to fit individual schedules. If you need to change your usual injection time, ensure there are at least 12 hours between doses to avoid double dosing, then try to maintain a regular pattern once established.

Storage requirements are important for maintaining medication efficacy. Unopened Saxenda pens should be stored in a refrigerator at 2°C to 8°C and protected from light. Once in use, the pen can be kept at room temperature (below 30°C) or in the refrigerator for up to one month. Never freeze Saxenda, and discard any pens that have been frozen. Always check the solution before injecting—it should be clear and colourless. If the solution appears cloudy, discoloured, or contains particles, do not use it.

Patients should never share their Saxenda pen with others, even if the needle is changed, due to the risk of infection transmission.

What Happens If You Miss a Daily Saxenda Dose

If you miss a dose of Saxenda, the recommended action depends on how much time has elapsed since your usual injection time. If you remember within 12 hours of when you normally inject, administer the missed dose as soon as possible. However, if more than 12 hours have passed since your scheduled injection time, skip the missed dose entirely and resume your regular dosing schedule with your next planned injection.

It is crucial never to take a double dose to make up for a missed one, as this significantly increases the risk of adverse effects, particularly gastrointestinal symptoms such as severe nausea, vomiting, and diarrhoea. Never administer two doses within 12 hours. Taking more than the prescribed daily dose can also increase the risk of hypoglycaemia (low blood sugar), especially in patients taking other glucose-lowering medications.

Consistent dosing helps maintain the medication's effectiveness in regulating appetite throughout the day. When doses are regularly missed, drug levels may fluctuate, potentially diminishing the appetite-suppressing effects and making it more difficult to adhere to dietary changes.

If you miss doses for more than 3 consecutive days, the UK product licence (SmPC) instructs that you should restart at 0.6 mg and re-titrate weekly according to the original schedule. This approach helps minimise gastrointestinal side effects that might occur if immediately returning to your maintenance dose of 3.0 mg.

To improve adherence, consider setting a daily alarm on your phone, keeping your Saxenda pen in a visible location (whilst maintaining proper storage conditions), or linking your injection to an existing daily routine such as brushing your teeth or having breakfast. If you find yourself frequently forgetting doses, discuss strategies with your GP or practice nurse to help establish a more consistent routine.

Daily Saxenda Use: Expected Results and Timeline

Weight loss with daily Saxenda use is gradual and varies between individuals, but clinical trials provide useful benchmarks for expected outcomes. In the pivotal SCALE trial, patients using Saxenda 3.0 mg daily alongside lifestyle modifications lost an average of 8% of their initial body weight over 56 weeks, compared to 2.6% in the placebo group. Approximately 63% of Saxenda users achieved at least 5% weight loss, whilst 33% lost 10% or more of their starting weight.

Initial weight loss typically becomes noticeable within the first 4–8 weeks of treatment, though this varies considerably. During the dose escalation phase (weeks 1–5), weight loss may be modest as your body adjusts to the medication and you're not yet at the full therapeutic dose. More substantial weight reduction generally occurs once the maintenance dose of 3.0 mg daily is reached and maintained consistently.

According to the UK product licence (SmPC), treatment response should be assessed after 12 weeks on the 3.0 mg maintenance dose. If you have not lost at least 5% of your initial body weight by this point, Saxenda should be discontinued, as continued use is unlikely to produce clinically meaningful results. This assessment ensures that the medication is only continued in patients who demonstrate an appropriate response, optimising both clinical outcomes and cost-effectiveness.

The rate of weight loss typically slows after the first few months as your body adapts to a lower calorie intake and reduced body weight. This plateau effect is normal and does not indicate treatment failure. Maintaining weight loss requires ongoing commitment to dietary changes and physical activity—Saxenda is not a standalone solution but rather a tool to support lifestyle modifications.

Common adverse effects during daily use include nausea (affecting approximately 40% of users), diarrhoea, constipation, vomiting, and headache. These gastrointestinal symptoms are usually most pronounced during dose escalation and often improve with continued use. Severe gastrointestinal symptoms may lead to dehydration and potential kidney problems. Some patients may experience increased heart rate or allergic reactions. Saxenda should not be used during pregnancy and should be discontinued if pregnancy occurs.

Patients should stop Saxenda immediately and seek urgent medical attention if they experience signs of pancreatitis (severe, persistent abdominal pain, sometimes radiating to the back), gallbladder problems (pain in the upper right abdomen, fever, yellowing of skin or eyes), or symptoms of depression or suicidal thoughts, as these require prompt medical assessment.

If you experience any suspected side effects, report them to the MHRA Yellow Card Scheme, which helps monitor the safety of medicines.

Frequently Asked Questions